← Oncology Approval Tracker

FDA DECISION ·

Mylotarg

gemtuzumab ozogamicin · Wyeth Pharmaceuticals

FDA approvalNew or expanded indicationAcute myeloid leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Expanded the newly diagnosed CD33-positive acute myeloid leukemia indication to children aged one month and older.

LAMPGEN ANALYSIS

Why it matters

Extended a CD33-directed antibody-drug conjugate to very young patients with newly diagnosed disease.

What research teams should watch

Document CD33 status and age-specific dosing and monitor liver complications around transplant.

PRIMARY RECORDS

Sources